Kuo Che-Ying, Baker Hannah, Fries Melissa H, Yoo James J, Kim Peter C W, Fisher John P
1 Fischell Department of Bioengineering, University of Maryland College Park , College Park, Maryland.
2 Sheikh Zayed Institute for Pediatric Surgical Innovation , Children's National Health System, Washington, District of Columbia.
Tissue Eng Part B Rev. 2017 Jun;23(3):294-306. doi: 10.1089/ten.TEB.2016.0385. Epub 2017 Feb 3.
Bioengineering strategies have demonstrated enormous potential to treat female infertility as a result of chemotherapy, uterine injuries, fallopian tube occlusion, massive intrauterine adhesions, congenital uterine malformations, and hysterectomy. These strategies can be classified into two broad categories as follows: (i) Transplantation of fresh or cryopreserved organs into the host and (ii) tissue engineering approaches that utilize a combination of cells, growth factors, and biomaterials that leverages the body's inherent ability to regenerate/repair reproductive organs. While whole organ transplant has demonstrated success, the source of the organ and the immunogenic effects of allografts remain challenging. Even though tissue engineering strategies can avoid these issues, their feasibilities of creating whole organ constructs are yet to be demonstrated. In this article we summarize the recent advancements in the applications of bioengineering to treat female infertility.
生物工程策略已显示出巨大潜力，可用于治疗因化疗、子宫损伤、输卵管阻塞、严重宫腔粘连、先天性子宫畸形和子宫切除导致的女性不孕症。这些策略可大致分为以下两大类：（i）将新鲜或冷冻保存的器官移植到宿主中；（ii）组织工程方法，即利用细胞、生长因子和生物材料的组合，借助身体再生/修复生殖器官的固有能力。虽然全器官移植已取得成功，但器官来源和同种异体移植的免疫原性影响仍然具有挑战性。尽管组织工程策略可以避免这些问题，但其构建全器官结构的可行性仍有待证明。在本文中，我们总结了生物工程在治疗女性不孕症应用方面的最新进展。
